For the Inventor, By the Inventor

Enter assignee name

Baltimore, MD, United States of America

Gliknik Inc.

USPTO Granted Patents = 17

CIPO Patents = 2

EPO Patents = 6

Trademarks = 1

Forward Citations = 147

Loading Chart...

Loading Chart...

5 inventors (with patents filed for the assignee):

David S Block (17 out of 17 patents)

Henrik Olsen (17 out of 17 patents)

Scott E Strome (7 out of 21 patents)

4. Dan H Schulze (7 out of 8 patents)

5. Emmanuel Y Mérigeon (3 out of 3 patents)

17 patents: Sort by Forward Citations

1. 12337026 - Methods of treating inflammatory disorders with multivalent Fc compounds (2025-06-24),

2. 12195499 - Manufacturing optimization of GL-2045, a multimerizing stradomer (2025-01-14),

3. 12122836 - Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin Fc compositions with enhanced complement binding (2024-10-22),

4. 12084482 - Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions (2024-09-10),

5. 11795193 - Manufacturing optimization of GL-2045, a multimerizing stradomer (2023-10-24),

6. 11331372 - Methods of treating inflammatory disorders with multivalent Fc compounds (2022-05-17),

7. 11155574 - Manufacturing optimization of GL-2045, a multimerizing stradomer (2021-10-26),

8. 11117940 - Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions (2021-09-14),

9. 11034775 - Cysteine-optimized stradomers (2021-06-15),

10. 10941191 - Immunoglobulin constant region Fc receptor binding agents (2021-03-09),

11. 10851154 - Immunoglobulin constant region Fc receptor binding agents (2020-12-01),

12. 10208105 - Immunoglobulin constant region Fc receptor binding agents (2019-02-19),

13. 9926362 - Immunoglobulin constant region Fc receptor binding agents (2018-03-27),

14. 9683044 - Molecules with antigen binding and polyvalent FC gamma receptor binding activity (2017-06-20),

15. 9512210 - Immunoglobulin constant region Fc receptor binding agents (2016-12-06),

Gliknik Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and immune-related disorders. With a commitment to improving patient outcomes, Gliknik utilizes cutting-edge technologies to design innovative antibody therapeutics and vaccines. Their research and development efforts are centered around targeting specific immune system components to enhance the body's natural defenses against diseases. By harnessing the power of the immune system, Gliknik aims to revolutionize the way various diseases are treated, offering new hope to patients around the world.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

17 Patents

#30 in Baltimore, MD

#262 in Maryland

#18,849 in US

#35,819 in the World

Baltimore, MD, United States of America

Gliknik Inc.

Forward Citations = 147

5 inventors:

David S Block (17 out of 17 patents)

Henrik Olsen (17 out of 17 patents)

Scott E Strome (7 out of 21 patents)

4. Dan H Schulze (7 out of 8 patents)

5. Emmanuel Y Mérigeon (3 out of 3 patents)

Please report any incorrect information to [email protected]

Loading…